Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Ameriprise Financial Inc. purchased a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 35,059 shares of the company’s stock, valued at approximately $789,000. Ameriprise Financial Inc. owned approximately 0.07% of Enliven Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its position in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after acquiring an additional 1,114 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth about $97,000. ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at $200,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after purchasing an additional 1,275 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Enliven Therapeutics by 17.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company’s stock worth $307,000 after acquiring an additional 1,980 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on ELVN. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 15th. Jones Trading reduced their target price on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $37.25.

Insiders Place Their Bets

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $16.18, for a total transaction of $52,585.00. Following the completion of the sale, the chief financial officer now owns 23,000 shares of the company’s stock, valued at approximately $372,140. The trade was a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the firm’s stock in a transaction on Monday, May 19th. The stock was sold at an average price of $16.31, for a total transaction of $81,550.00. Following the transaction, the insider now directly owns 985,188 shares of the company’s stock, valued at approximately $16,068,416.28. This represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,111 shares of company stock worth $1,643,398 in the last ninety days. 29.20% of the stock is owned by corporate insiders.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $19.14 on Tuesday. The stock has a market capitalization of $939.18 million, a price-to-earnings ratio of -10.07 and a beta of 1.07. The stock’s 50-day simple moving average is $17.98 and its two-hundred day simple moving average is $20.86. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.